Rice Hall James & Associates LLC Grows Position in Teleflex Incorporated (TFX)

Rice Hall James & Associates LLC lifted its position in Teleflex Incorporated (NYSE:TFX) by 31.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 135,882 shares of the medical technology company’s stock after acquiring an additional 32,784 shares during the period. Teleflex accounts for approximately 1.3% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 12th biggest holding. Rice Hall James & Associates LLC’s holdings in Teleflex were worth $33,810,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TFX. Teachers Advisors LLC increased its position in shares of Teleflex by 8.2% in the 2nd quarter. Teachers Advisors LLC now owns 51,393 shares of the medical technology company’s stock valued at $10,677,000 after acquiring an additional 3,875 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Teleflex by 1.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 23,740 shares of the medical technology company’s stock valued at $4,934,000 after acquiring an additional 231 shares during the period. New York State Common Retirement Fund increased its position in shares of Teleflex by 5.1% in the 2nd quarter. New York State Common Retirement Fund now owns 110,577 shares of the medical technology company’s stock valued at $22,973,000 after acquiring an additional 5,386 shares during the period. UBS Asset Management Americas Inc. increased its position in shares of Teleflex by 14.9% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 106,993 shares of the medical technology company’s stock valued at $22,229,000 after acquiring an additional 13,878 shares during the period. Finally, Citigroup Inc. increased its position in shares of Teleflex by 37.3% in the 2nd quarter. Citigroup Inc. now owns 10,062 shares of the medical technology company’s stock valued at $2,091,000 after acquiring an additional 2,731 shares during the period. 89.32% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director George Babich, Jr. sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $263.38, for a total transaction of $658,450.00. Following the sale, the director now directly owns 10,583 shares in the company, valued at approximately $2,787,350.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $248.96, for a total value of $49,792.00. Following the sale, the director now owns 8,080 shares in the company, valued at $2,011,596.80. The disclosure for this sale can be found here. Insiders have sold a total of 5,100 shares of company stock worth $1,324,942 over the last 90 days. Insiders own 2.39% of the company’s stock.

Shares of Teleflex Incorporated (TFX) traded down $1.67 on Tuesday, reaching $274.75. The company’s stock had a trading volume of 196,200 shares, compared to its average volume of 272,957. The firm has a market cap of $12,452.52, a P/E ratio of 50.14, a P/E/G ratio of 2.04 and a beta of 1.09. The company has a debt-to-equity ratio of 0.88, a current ratio of 4.72 and a quick ratio of 3.70. Teleflex Incorporated has a 12 month low of $162.79 and a 12 month high of $279.12.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.11. The company had revenue of $534.70 million for the quarter, compared to the consensus estimate of $522.94 million. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The firm’s revenue for the quarter was up 17.3% compared to the same quarter last year. During the same period last year, the firm earned $1.80 EPS. analysts predict that Teleflex Incorporated will post 8.36 earnings per share for the current fiscal year.

Several research firms recently issued reports on TFX. Morgan Stanley upped their target price on Teleflex from $274.00 to $290.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Deutsche Bank downgraded Teleflex from a “buy” rating to a “hold” rating and set a $251.00 price target on the stock. in a research report on Tuesday, November 14th. Needham & Company LLC increased their price target on Teleflex from $237.00 to $285.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. Jefferies Group increased their price target on Teleflex from $270.00 to $295.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. Finally, Zacks Investment Research downgraded Teleflex from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $277.78.

TRADEMARK VIOLATION NOTICE: “Rice Hall James & Associates LLC Grows Position in Teleflex Incorporated (TFX)” was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.com-unik.info/2018/01/23/rice-hall-james-associates-llc-grows-position-in-teleflex-incorporated-tfx.html.

Teleflex Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit